Impact of natalizumab on patient-reported outcomes in a clinical practice setting: A cross-sectional survey

Patient

Volumn 2, Issue 2, 2009, Pages 105-112

  Kamat, Siddhesh A ^a   Rajagopalan, Krithika ^b   Stephenson, Judith J ^a   Agarwal, Sonalee ^b  

^a HEALTHCORE INC   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; DISEASE DURATION; DRUG INFUSION; EDUCATIONAL STATUS; EMPLOYMENT STATUS; ETHNICITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FUNCTIONAL STATUS; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 77953470438     PISSN: 11781653     EISSN: 11781661     Source Type: Journal    
DOI: 10.2165/01312067-200902020-00006     Document Type: Article

References (19)

1. Sadovnick AD, Ebers GC. Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci 1993; 20:17-29
2. National Multiple Sclerosis Society. Symptoms [online].Available from URL: http://www.nationalmssociety.org/about-multiple-sclerosis/symptoms/index. aspx. 2008 [Accessed 2008 Jul 24]
3. Benito-Leon J, Morales JM, Rivera-Navarro J, et al. A review about the impact of multiple sclerosis on health-related quality of life. Disabil Rehabil 2003; 25: 1291-303
4. Nortvedt MW, Riise T. The use ofquality oflife measures inmultiple sclerosis research. Mult Scler 2003; 9: 63-72
5. Sprangers MA, de Regt EB, Andries F, et al. Which chronic conditions are associated with better or poorer quality of life? J Clin Epidemiol 2000; 53: 895-907
6. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52
7. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910
8. Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007; 62: 335-46
9. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989; 112 (Pt 1): 133-46
10. US Food and Drug Administration. Natalizumab (marketed as Tysabri) information [online]. Available from URL: http://www.fda.gov/cder/drug/infopage/ natalizumab [Accessed 2008 Jul 25]
11. Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology 1995; 45: 251-5
12. Hobart J, Lamping D, Fitzpatrick R, et al. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 2001; 124: 962-73
13. Goodin DS. A questionnaire to assess neurological impairment in multiple sclerosis. Mult Scler 1998; 4: 444-51
14. Hohol M, Orav E, Weiner H. Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler 1999; 5:349-54
15. The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis. Part II: quality of life. Can J Neurological Sci 1998; 25: 31-8
16. Miller DM, Rudick RA, Cutter G, et al. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch Neurol 2000; 57:1319-24
17. Rothwell P, McDowell Z, Wong C, et al. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. BMJ 1997; 314: 1580-3
18. Tysabri (natalizumab) [package insert]. Cambridge (MA):Biogen Idec Inc., 2008
19. Palferman TG. Principles of rheumatoid arthritis control. J Rheumatol Suppl 2003 Aug; 67: 10-3